Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Schedule of Unrealized Loss and Fair Values in a Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Area of leased property (sqft) Area of Real Estate Property Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Property and equipment, gross Property, Plant and Equipment, Gross Number of shares, Restricted stock units expected to vest (in dollars per share) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Additional paid in capital Additional Paid in Capital Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties Financial Instruments [Domain] Financial Instruments [Domain] By the end of 2026 First Installment [Member] First Installment Statistical Measurement [Domain] Statistical Measurement [Domain] Shares issued under employee stock plans (in shares) Exercises (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Initial offering period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Offering Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Offering Period Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Non-cash interest expense Other Noncash Income (Expense) Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount GSK GlaxoSmithKline [Member] GlaxoSmithKline Equity Component [Domain] Equity Component [Domain] First MAA approval - first indication First Marketing Authorization Application Approval - First Indication [Member] First Marketing Authorization Application Approval - First Indication Lease term Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Monthly base rate (in dollars per sqft) Rent Per Square Foot Rent Per Square Foot Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Available-for-sale securities, debt securities Total Fair Value Debt Securities, Available-for-Sale Remaining maturity (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Maximum milestone payments per target (up to) Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grantsed Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grantsed Plan Name [Domain] Plan Name [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] ESPP Employee Stock [Member] Royalty Agreement, Above $1.0 billion Royalty Agreement, Above $1. 0 billion [Member] Royalty Agreement, Above $1. 0 billion Weighted average remaining contractual term, options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liability Operating Lease, Liability, Current Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Filing of the first BLA - second indication Filing of Biologics License Application - Second Indication [Member] Filing of Biologics License Application - Second Indication Certificates of deposit Certificates of Deposit [Member] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] First BLA approval - first indication First Biologics License Application Approval - dMMREC [Member] First Biologics License Application Approval - dMMREC BMS Bristol-Myers Squibb [Member] Bristol-Myers Squibb Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Schedule of Property and Equipment, net Property, Plant and Equipment [Table Text Block] Short-term investments Debt Securities, Available-for-Sale, Current Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Forfeitures and cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Weighted average grant date fair value, beginning balance (in dollars per share) Weighted average grant date fair value, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Financial Instrument [Axis] Financial Instrument [Axis] Schedule of Royalty Transaction Activity Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties Interest income Interest Income, Other Total assets Assets Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Net loss per common share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued expenses Total accrued expenses Accrued Liabilities, Current Exercises (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Proceeds from sale of future royalties Proceeds From Advance Future Royalties Proceeds From Advance Future Royalties Accounting Policies [Abstract] Accounting Policies [Abstract] Accrued compensation and related expenses Employee-related Liabilities, Current Royalties Royalty Agreement [Member] Royalty Agreement Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Schedule of Weighted Average Assumptions used to Estimate Fair Value Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Anti-LAG-3 (GSK40974386) AnaptysBio Generated Anti-LAG-3 (GSK40974386) [Member] AnaptysBio Generated Anti-LAG-3 (GSK40974386) AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Award Type [Domain] Award Type [Domain] Weighted average period remaining for amortization of unrecognized compensation cost (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Weighted average remaining contractual term, options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Sagard Sagard Healthcare Royalty Partners, LP [Member] Sagard Healthcare Royalty Partners, LP Royalties and milestones, agreement amount to be received Advance Future Royalties, Aggregate Payment, Threshold Advance Future Royalties, Aggregate Payment, Threshold Entity Registrant Name Entity Registrant Name Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Entity Address, City or Town Entity Address, City or Town Operating expenses: Operating Expenses [Abstract] Mutual Funds Mutual Fund [Member] Basis of Consolidation Consolidation, Policy [Policy Text Block] Lease renewal term Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Minimum Minimum [Member] Award equivalent shares Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] AnaptysBio-generated Zejula and JEMPERLI Zejula and AnaptysBio-generated JEMPERLI [Member] Zejula and AnaptysBio-generated JEMPERLI Trading Symbol Trading Symbol Entity File Number Entity File Number Internal rate of return percentage Advance Future Royalties, Internal Rate Of Return Advance Future Royalties, Internal Rate Of Return Research and development Research and Development Expense Title of Individual [Axis] Title of Individual [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Proceeds, contingent on annual sales milestones upfront percentage Advance Future Royalties, Aggregate Payment, Threshold Percent Advance Future Royalties, Aggregate Payment, Threshold Percent Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 months or greater, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Basic (in dollars per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Net sales royalty Net Sales Royalty Threshold Net Sales Royalty Threshold Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Stockholders' equity, beginning balance Stockholders' equity, ending balance Stockholders' Equity Attributable to Parent Directors Director [Member] Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Entity Interactive Data Current Entity Interactive Data Current Regulatory Regulatory [Member] Regulatory Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Non cash share based compensation expense Share-Based Payment Arrangement, Accelerated Cost Money Market Funds Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Common Stock Common Stock [Member] Zejula Zejula [Member] Zejula Sale of Future Royalties Sale Of Future Royalties Text Block [Text Block] Sale Of Future Royalties Text Block Schedule of Costs in Cash Flow Statement Lease, Cost [Table Text Block] Number of reportable segments Number of Reportable Segments Shares reserved for future award grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Receivables from collaborative partners Receivables, Net, Current Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Agreement term following first commercial sale or expiration of the last to expire patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Equity Components [Axis] Equity Components [Axis] Number of shares, Restricted stock units expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Recurring Fair Value, Recurring [Member] Weighted-average exercise price per share, Stock options exercisable, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Revenue recognition multiple deliverable arrangements upfront fee receivable Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Less than 12 months, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Document Fiscal Year Focus Document Fiscal Year Focus CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Number of shares, beginning balance (in shares) Number of shares, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total other income (expense), net Nonoperating Income (Expense) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Activity Related to Stock Option Awards Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Issuance of common stock from exercises of options and employee stock purchase plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Stock Issued During Period, Value, Options and Employee Stock Purchase Plan Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Weighted-average number of shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Name of Property [Domain] Name of Property [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Anti-PD-1 (JEMPERLI/Dostarlimab) AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) Unrealized losses on available-for-sale Debt Securities, Available-for-Sale, Unrealized Loss Annual increase in number of shares available for issuance percentage Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Non-cash interest expense recognized Noncash Interest Expense Recognized Noncash Interest Expense Recognized First BLA approval - second indication First Biologics License Application Approval - Second Indication [Member] First Biologics License Application Approval - Second Indication Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] GlaxoSmithKline Collaboration Collaborative Arrangement [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Schedule of Available-for-sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Weighted average remaining contractual term, other than options vested and expected to vest (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms Common stock, $0.001 par value, 500,000 shares authorized, 28,231 shares and 27,647 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Milestone payments, contingent upon preclinical and clinical trial events (up to) Total Contractual Milestones Remaining Revenue Recognition, Milestone Method, Contingent Upon Pre Clinical, Regulatory And Commercial Events Revenue Recognition, Milestone Method, Contingent Upon Pre Clinical, Regulatory And Commercial Events Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Royalties agreement, maximum annual royalty payout capacity Advance Future Royalties, Annual Sales Threshold Advance Future Royalties, Annual Sales Threshold Aggregate intrinsic value, restricted stock units expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Aggregate intrinsic value, options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Interim President and Chief Executive Officer Interim President And Chief Executive Officer [Member] Interim President And Chief Executive Officer Common stock, shares issued (in shares) Common Stock, Shares, Issued Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Weighted average remaining contractual term, other than options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Royalty percent on net sales Net Sales Royalty, Percent Net Sales Royalty, Percent Comprehensive loss, net Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Non-cash interest expense for the sale of future royalties Noncash Advance Future Royalties, Interest Expense Noncash Advance Future Royalties, Interest Expense Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other long-term assets Other Assets, Noncurrent Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Shares subject to options, exercisable, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Security deposit Security Deposit Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] CEO Chief Executive Officer [Member] Counterparty Name [Axis] Counterparty Name [Axis] Stock options (in shares) Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Pre clinical and Development Pre Clinical and Development [Member] Pre Clinical and Development Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Office furniture and equipment Office Equipment [Member] Options to purchase common stock Stock Options Share-Based Payment Arrangement, Option [Member] Title of Individual [Domain] Title of Individual [Domain] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Shares issued under employee stock plans Stock Issued During Period, Value, Stock Options Exercised Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Issuance of common stock from exercises of options and employee stock purchase plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan Other income, net Other Nonoperating Income (Expense) Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment Unrealized loss on available for sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares authorized (in shares) Common Stock, Shares Authorized Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] Total operating expenses Operating Expenses Maximum Maximum [Member] Receivable related to issuance of common stock, upon exercise of stock options Receivables for Stock Options Exercised Receivables for Stock Options Exercised Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Lease termination term Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Entity Small Business Entity Small Business Stockholders' equity, beginning balance (in shares) Stockholders' equity, ending balance (in shares) Shares, Outstanding Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Measurement Frequency [Domain] Measurement Frequency [Domain] Amortization of right-of-use assets – operating Operating Lease, Right-of-Use Asset, Amortization Expense Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Shares Subject to Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Increase in annual rent percentage Annual Rent Increase, Percent Annual Rent Increase, Percent Aggregate intrinsic value, options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security 2017 Equity Incentive Plan Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Liability related to sale of future royalties Advance Future Royalties, Liability, Noncurrent Advance Future Royalties, Liability, Noncurrent Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Issued and Outstanding: Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Amendment Collaboration and Exclusive License Agreement [Member] Collaboration and Exclusive License Agreement Class of Stock [Line Items] Class of Stock [Line Items] Less than 12 months, Gross unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Payments for debt issuance costs Payments of Debt Issuance Costs Lease liability Total Operating Lease, Liability Agency securities US Government Agencies Debt Securities [Member] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties 12 months or greater, Gross unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] US Treasury Securities US Treasury Securities [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Forfeitures and cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Filing of the first MAA - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Accounts payable Accounts Payable, Current 2017 Employee Stock Purchase Plan Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Description of the Business Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Filing of the first BLA - first indication Filing of Biologics License Application - First Indication [Member] Filing of Biologics License Application - First Indication Noncash advance future royalties revenue Noncash Advance Future Royalties Revenue Noncash Advance Future Royalties Revenue Stock based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other Liabilities Disclosure [Abstract] Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June 30, 2022 and December 31, 2021, respectively Preferred Stock, Value, Issued Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative General and Administrative Expense [Member] Collaboration revenue Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Common stock, shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Cover [Abstract] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Long-term investments Debt Securities, Available-for-Sale, Noncurrent Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Royalty Agreement, Up To $1.0 billion Royalty Agreement, Up To $1. 0 billion [Member] Royalty Agreement, Up To $1. 0 billion Schedule of Non-cash Stock-based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Receivables from collaborative partners Increase (Decrease) in Contract with Customer, Asset Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate At any time after 2027 Third Installment [Member] Third Installment Total liabilities and stockholders’ equity Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Liability related to sale of future JEMPERLI royalties and milestones - balance at 12/31/2021 Liability related to sale of future royalties and milestones - ending balance Advance Future Royalties, Liabilities Advance Future Royalties, Liabilities Repayment of liability for sale of future royalties Royalty and milestone payments to Sagard Advance Future Royalty And Milestone Payments Advance Future Royalty And Milestone Payments Milestones achieved, amount Revenue Recognition, Milestone Method, Milestones Achieved During, Amount Revenue Recognition, Milestone Method, Milestones Achieved, Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (in dollars per share) Earnings Per Share, Diluted Effective interest rate Advance Future Royalties, Interest Rate, Effective Percentage Advance Future Royalties, Interest Rate, Effective Percentage Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Total current liabilities Liabilities, Current Issuance costs related to the sale of future royalties Issuance costs related to the sale of future royalties Advance Future Royalties, Issuance Costs Advance Future Royalties, Issuance Costs 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of Time-based Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other income (expense), net: Nonoperating Income (Expense) [Abstract] Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One During 2027 Second Installment [Member] Second Installment Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Amounts accrued for issuance costs related to the sale of future royalties Noncash Advance Future Royalties, Issuance Costs, Incurred but Not yet Paid Noncash Advance Future Royalties, Issuance Costs, Incurred but Not yet Paid Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member] AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) Former CEO Former Chief Executive Officer [Member] Former Chief Executive Officer Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Commercial Commercial [Member] Commercial Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Equity [Abstract] Equity [Abstract] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Restricted stock units (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Revenue from Contract with Customer [Abstract] Stock-based compensation APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Amortization of issuance costs Amortization Of Advance Future Royalties Issuance Costs Amortization Of Advance Future Royalties Issuance Costs Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Name of Property [Axis] Name of Property [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] Other Other Accrued Liabilities, Current City Area Code City Area Code Accrued professional fees Accrued Professional Fees, Current General and administrative General and Administrative Expense ASSETS Assets [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock-based compensation Non-cash stock-based compensation cost Share-Based Payment Arrangement, Noncash Expense Weighted average grant date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member] Collaboration Revenue [Member] Collaboration Revenue